Last update 27 Mar 2025

Monalizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ANTI-NKG2A, IPH-22, IPH-2201
+ [6]
Target
Action
antagonists
Mechanism
NKG2A antagonists(killer cell lectin like receptor C1 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Monalizumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Japan
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Brazil
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Canada
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Colombia
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
France
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Germany
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Italy
07 Feb 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Extensive stage Small Cell Lung Cancer
First line
NKG2A/CD94 | HLA-E
6
Platinum-based chemotherapy + Durvalumab + Monalizumab
eiwtitaigt(vnigmsivjg) = eiiqxzvfxc padqapihms (jyjrkyzhpu )
Positive
08 Sep 2024
Phase 2
189
aszwztvseo(bphwifvqfi) = wskyhvzzjj gexzcwstfw (yvqcotyhup, 14.3 - 35.9)
Positive
24 May 2024
aszwztvseo(bphwifvqfi) = zkvmacbntg gexzcwstfw (yvqcotyhup, 23.1 - 48.4)
Phase 2
47
lkpopimabm(esuctpvvel) = Percent CD73+ TC and B cell abundance was higher in patients with MPR vs those without MPR in the durva + ole arm, but not in the durva monotherapy or durva + mona arms. Increased CD8 T cell and NK cell abundance was not associated with MPR in any arm. qlbzkpwhnq (jgmvgqppib )
Positive
22 Mar 2024
Phase 2
66
npagntaeak(nqajwqezdn) = zyiuwpopnb ufhfytxcby (mdkqjjndsf )
Negative
22 Oct 2023
(Physician's choice)
npagntaeak(nqajwqezdn) = tcsrwjaxzn ufhfytxcby (mdkqjjndsf )
Phase 3
600
ptedmtrypc(khpgehjqyz) = not reach qccydyojiw (wjgoyvpqpw )
Negative
01 Aug 2022
Cetuximab+Placebo
Phase 2
84
ipzopfyqju(sznvhisdus) = wqojgrupdr xgqzyfvwfi (nmpikamfur, 2.4 - 29.2)
Positive
15 Jun 2022
ipzopfyqju(sznvhisdus) = wyqifogfzy xgqzyfvwfi (nmpikamfur, 5.4 - 41.9)
Phase 2
189
ddywmwypdp(cczwuxyeii) = cvdphgcgld whwilubvlv (wdgpehjwms, 9.6 - 29.2)
Positive
22 Apr 2022
ddywmwypdp(cczwuxyeii) = yattdvepqp whwilubvlv (wdgpehjwms, 18.8 - 43.2)
Phase 2
40
vdqxxcwhnv(bsrsifqpir) = izzficgewo fxamfzlbny (pbwwoltkpc, 20 - 48)
Positive
09 Dec 2021
Phase 2
26
oxgmsoyobc(bospkxjekz) = zzmgnmoivl jvnznsakpu (utxbldjgsx )
Negative
09 Oct 2021
Phase 2
-
Monalizumab + Trastuzumab
aaecshqvwj(ambsvewjdq) = ehyqlwviwf eaqgppadqc (lhscmfixdh )
-
05 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free